ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)

被引：0
|
作者：
Trevino, Tracy [1 ]
Kopetz, Scott [1 ]
Grothey, Axel [2 ]
Yaeger, Rona [1 ]
Sandor, Victor [3 ]
Velez, Lydia [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] West Canc Ctr & Res Inst, Germantown, TN USA
[3] Pfizer Inc, New York, NY USA
[4] Vail dHebron Univ Hosp, Vail dHebron Inst Oncol, Barcelona, Spain
来源：
ONCOLOGY NURSING FORUM | 2020年 / 47卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
457
引用
收藏
页数：1
相关论文
共 50 条
  • [1] BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Kopetz, S.
    Crothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Gollerkeri, F.
    Maharry, K.
    Loupakis, F.
    Hong, Y.
    Steeghs, F.
    Guren, T.
    Arkenau, H.
    Garcia Alfonso, P.
    Sandor, V.
    Christy-Bittel, J.
    Anderson, L.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Tabernero, J.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. Sang
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T.
    Garcia-Alfonso, P.
    Gollerkeri, A.
    Pickard, M.
    Maharry, K.
    Christy-Bittel, J. L.
    Anderson, L.
    Kopetz, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 868 - 868
  • [3] BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Desai, Jayesh
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia Alfonso, Pilar
    Price, Timothy
    Strickland, Andrew
    Tebbutt, Niall
    Karapetis, Christos
    Chantrill, Lorraine
    Murphy, Felicity
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 99 - 99
  • [4] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
    Wasan, Harpreet
    Arkenau, Tobias
    Braun, Mike
    Samuel, Leslie
    Graham, Janet
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
  • [5] Beacon Crc: a Randomized, Phase 3 Study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BiNI) vs. Choice of Either Irinotecan or Folfiri Plus Cetux in BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)
    Vogel, Arndt
    Hegewisch-Becker, Susanna
    Prager, Gerald
    Folprecht, Gunnar
    Stahl, Michael
    Kopetz, Scott
    Grothey, Axel
    van Cutsetn, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Loupakis, Fotios
    Hong, Y.
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfons, Pilar
    Sandor, Victor
    Christy-Bittel, Farina
    Anderson, Lisa
    Tabernero, Josep
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 55 - 55
  • [6] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfonso, Pilar
    Gollerkeri, Ashwin
    Maharry, Kati
    Christy-Bittel, Janna
    Keir, Christopher Hunt
    Pickard, Michael D.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Kyrre Guren, Tormod
    Arkenau, Hendrik-Tobias
    Garcia-Alfonso, Pilar
    Gollerkeri, Ashwin
    Maharry, Kati
    Christy-Bittel, Janna
    Hunt Keir, Christopher
    Pickard, Michael D.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Price, Timothy
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Loupakis, Fotios
    Hong, Yong S.
    Steeghs, Neeltje
    Guren, Tormod K.
    Arkenau, Hendrik-Tobias
    Garcia-Alfonso, Pilar
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Karapetis, Chris
    Murphy, Felicity
    Gollerkeri, Ashwin
    Maharry, Kati
    Christy-Bittel, Janna
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 128 - 128
  • [9] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)
    Velez, L.
    Trevino, T.
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Gollerkeri, A.
    Maharry, K.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S224 - S225
  • [10] Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfonso, Pilar
    Gollerkeri, Ashwin
    Maharry, Kati
    Christy-Bittel, Janna
    Keir, Christopher Hunt
    Pickard, Michael D.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345